Erythropoietin (Epo), protein and iron supplementation and the prevention of anaemia of prematurity: effects on serum immunoreactive Epo, growth and protein and iron metabolism
1996; Wiley; Volume: 85; Issue: 4 Linguagem: Inglês
10.1111/j.1651-2227.1996.tb14069.x
ISSN1651-2227
AutoresA. G. Bechensteen, S Halvorsen, P Hågå, P. Mary Cotes, Knut Liestøl,
Tópico(s)Mesenchymal stem cell research
ResumoThe effect of recombinant human (r‐Hu) erythropoietin (Epo) (300 IU/kg per week for 4 weeks) was studied in healthy preterm infants ( n = 14) fed human milk with additional milk protein and high doses of iron. The controls ( n = 15) were in themselves a study group and were used to follow the natural course of anaemia of prematurity on such nutrition. Serum immunoreactive Epo (SiEpo) increased significantly 24h after r‐HuEpo injections (range 36 to > 128 mU/ml) and remained at these levels throughout the treatment period. r‐HuEpo in such moderate doses kept haemoglobin above 11 g/dl. Bodyweight gain, protein and iron parameters indicated adequacy of dietary protein and iron. In controls, siEpo increased during the first weeks after nutritional supplementation, with a concommitant rise in reticulocyte count. At age 3 weeks, despite low siEpo levels, reticulocyte counts indicated active erythropoiesis. Following further moderate increases in siEpo, the reticulocyte count increased to high levels (7%). The reticulocyte response suggests that erythropoiesis in preterm infants is less dependent upon Epo levels than in adults.
Referência(s)